# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Stoke Therapeutics (NASDAQ:STOK) with a Overweight.
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of...